open.michigan

Author(s): Aken Desai, Michael Mathis, 2008

License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution â€“ Share Alike 3.0
License: http://creativecommons.org/licenses/by-sa/3.0/

We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it.

Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content.

For more information about how to cite these materials visit http://open.umich.edu/education/about/terms-of-use.

Student works are presented as is and may be an interpretation of faculty members' lectures or assignments. These student works are not a product of faculty members. Faculty do not guarantee the accuracy of student work nor endorse them in any way.

Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.

MUNIVERSITY OF MICHIGAN

CC BY SA

Lecture Page 6

# Complement Self-Study Module

Tuesday, February 12, 2008

8:00 AM

- Complement Cascade
- Proteins produced in liver to direct pathogen destruction; covalently bound and more permanent
- Once one complement protein binds, multiple proteins bind all directing towards cell injury

- Complement Pathways
- Classical - begins w/ antigen-antibody binding --&gt; adaptive immune response
- Lectin - begins w/ non-specific protein binding to antigen --&gt; innate
- Alternative - begins w/ complement binding --&gt; innate
- All lead to covalent binding of C3b to pathogen
- 3 possible outcomes: opsonization, inflammation, lysis

- Activation of complements
- Most proteins have naming as C#(a/b)
- Each C protein is cleaved into a/b fragments by convertases
- "a" fragment may have something to do w/ inflammation
- "b" fragment is usually covalently bound

- Classical Pathway
- Antibody binds to antigen
- C1q binds to antibody (r, s have enzymatic activity)
- C1q only binds to IgM (pentameric, so only one needed) or IgG (multiple needed)
- C1q --&gt; C1r --&gt; C1s --&gt; cleavage of C4 to reveal thioester bond on C4b for nucleophilic attack
- C4b then binds to pathogen; C1s then cleaves C2 into C2a and C2b
- C2b non-covalently associates w/C4b to make C3 convertase of the classical pathway (C4b,2b)
- Convertase up to 1000 C3 --&gt; C3a + C3b
- C3b binds to pathogen surface

- Lectin Pathway
- Mannose binding protein binds to mannose, structurally similar to C1
- Non-specific
- Mannose found on many pathogens
- Virtually identical to classical pathway for the next steps

- Alternative Pathway
- Auto activation of C3--&gt;spontaneous C3 cleavage
- C3b binds to cell surface
- Factor B associates to C3b and is cleaved by complement D to Ba and Bb
- C3b,Bb stabilized by properdin
- C3b,Bb,properdin = C4b,2b
- Multiple C3b's bind to cell surface = amplification
- Same is possible for classical and lectin pathways

- Opsonization
- Macrophages have CR1 which recognizes C3b and C4b (negligible)
- This makes it easier for phagocytosis to take place

- Inflammation
- Small fragments released (a fragments)
- C3a, C5a, C4a (lesser extent) mediate inflammation --&gt; anaphylatoxins
- Stimulate degranulation of mast cells --&gt; release histamine --&gt; similar to anaphylactic rxn
- Anaphylatoxins + Mast cell mediators --&gt; aid macrophage adhesion/migration to cell wall
- C5a works as chemoattractant for neutrophils/monocytes

- MAC complex
- Complex of proteins to form pore in cell --&gt; open flow of water and ions to eventually cause lysis

of cell

- C3b + C3 convertase = C5 convertase
- C5b complexes w/ convertase --&gt; C6, C7, C8
- C7,C8 have hydrophobic regions to insert into membrane
- Up to 20 C9 molecules insert into membrane to form pore

- Immune Complexes can lead to classical pathway activation
- Circulating RBCs have CR1
- RBCs bind to immune complexes and carry the complexes out of circulation
- Classical pathway important in removal of circulating immune complexes

- Other Outcomes
- Breakdown products --&gt; B cell activation via CR2

- Complement Deficiencies
- Deficiencies in C1, C4, C2 --&gt; inability to remove immune complexes from circulation
- Injury by depositing in basement membrane of body tissues
- Arthritis, renal problems, rash; similar to lupus
- C2 deficiency is most common (1/10,000)
- Alternative pathway deficiencies
- Problems w/ opsonization, phagocytosis
- Increased risk of pyogenic bacterial infection
- Deficiencies in C5-9
- Inability to from membrane attacking complex
- Important in neisserial defense
- Increased risk of neisserial infection
- Deficiencies in MBP
- Recurrent pyogenic infection
- Failure to thrive

- Regulation
- Nothing to stop complements from binding to host cells
- Host cells must have something to prevent
- DAF - GPI anchored protein
- Prevents binding of C3b and Bb to make C5 convertases
- Can also cause dissociation of C5 convertases
- Inhibits all 3 pathways
- Defects in GPI anchor --&gt; paroxysmal nocturnal hemoglobinuria prob due to increased susceptibility to complement attack
- C1-INH
- C1 inhibitor
- Deficiency: hereditary angioneurotic edema
- Too much C4a, C2a
- Causes edema --&gt; laryngeal particularly problematic b/c of suffocation
- Treated w/ infusion of C1-INH
- Protectin (CD-59)
- GPI anchored
- Inhibits formation of MAC
- Membrane Cofactor Protein: Acts as cofactor for proteolytic cleavage of C3b by factor I
- CR1
- Membrane bound receptor
- Protects host cells by inhibiting association of convertases
- Can act as cofactor for factor I
- Factor I: Plasma protein that cleaves C4b, C3b
- Factor H: combines w/ C3b just like factor B but prevents factor B from binding
- Polyanionic environment of host cells due to sialic acid favors factor H binding
- Bacteria do not have same environment so factor B binds

Lecture Page 7

Lecture Page 8

- Serum Carboxypeptidase N (SCPN): Breaks down anaphylatoxins

- Clinical Testing
- Serum Complement Hemolytic Activity
- RBCs coated w/ antibodies
- Dilution of pt. serum added
- Classical pathway should be activated and RBCs should be lysed
- More active --&gt; should be able to dilute more
- Report 50% dilution: half of RBCs lysed